Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	127.11	218.04	293.48	507.14	79.45
Short-Term Investments	907.41	1,118	571.93	962.55	335.91
Cash & Cash Equivalents	1,035	1,336	865.41	1,470	415.36
Cash Growth	-22.58%	54.40%	-41.12%	253.84%	-10.54%
Other Current Assets	29.63	36.1	31.83	25.96	14.68
Total Current Assets	1,064	1,372	897.23	1,496	430.03
Property, Plant & Equipment	71.64	74.52	69.61	73.46	80.66
Long-Term Investments	0	0	425.45	32.7	39.89
Other Long-Term Assets	18.14	13.4	11.87	2.46	2.66
Total Long-Term Assets	89.78	87.92	506.93	108.63	123.2
Total Assets	1,154	1,460	1,404	1,604	553.23
Accounts Payable	9.48	2.79	4.78	1.07	2.59
Current Debt	7.26	0	0	0	0
Other Current Liabilities	61.24	361.13	373.47	70.63	42.75
Total Current Liabilities	77.98	363.92	378.25	71.7	45.34
Long-Term Debt	44.98	53.03	58.55	64.18	68.87
Other Long-Term Liabilities	0	0.86	5.07	317.88	44.13
Total Long-Term Liabilities	44.98	53.89	63.63	382.05	113
Total Liabilities	122.96	417.81	441.87	453.75	158.34
Total Debt	52.24	53.03	58.55	64.18	68.87
Debt Growth	-1.49%	-9.43%	-8.76%	-6.81%	-
Retained Earnings	-1,116.21	-970.99	-645	-354.42	-425.55
Comprehensive Income	0.64	-6.89	-2.5	-0.25	0.35
Shareholders' Equity	1,031	1,042	962.29	1,151	394.89
Net Cash / Debt	982.27	1,283	806.85	1,406	346.49
Net Cash / Debt Growth	-23.45%	59.04%	-42.59%	305.64%	-25.37%
Net Cash Per Share	7.15	10.22	6.64	-	3.62
Working Capital	986.16	1,008	518.99	1,424	384.69
Book Value Per Share	7.50	8.30	7.92	9.59	4.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).